ArticleJournal of ovarian research2025
Deciphering the molecular landscape of NMDAR-E associated ovarian teratomas: a Multi-Omics approach.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAnti-N-methyl-D-aspartate receptor encephalitis (NMDAR-E) is an autoimmune disorder often associated with ovarian teratomas. It involves antibodies against the neuronal NMDAr1 subunits of NR1, but the pathogenesis and molecular mechanisms are not fully understood. To identify significantly differentially expressed genes and proteins and investigate the intricate molecular regulatory network underlying anti-NMDA receptor encephalitis (NMDAR-E) associated with ovarian teratomas.
methodsThis retrospective study analyzed ovarian teratoma samples from patients with and without NMDAR-E. RNA sequencing and iTRAQ coupled LC-MS/MS analysis were used for gene and protein expression profiling. qPCR and western blotting were used to validate the gene and protein expression.
resultsWe identified 2524 significantly differentially expressed genes and 34 proteins. The changes were notable at the mRNA and protein levels in ovarian teratomas associated with NMDAR-E. Functional enrichment analysis highlighted the extracellular matrix and immune activation pathways. Key genes and proteins involved in ferroptosis and immune activation, including SLC40A1, GGH, FKBP11, CCDC80, and ANK3, showed significant expression differences.
conclusionsOur findings provide preliminary insights into the pathophysiology of NMDAR-E associated with ovarian teratomas. These results may generate hypotheses for future mechanistic studies, and the candidate biomarkers identified warrant further validation before clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.